Analysts Viewpoint H.C. Wainwright reiterates Eton Pharmaceuticals Inc (ETON) rating to a Buy Eton Pharmaceuticals Inc’s filing revealed that its Chief Business Officer Krempa David unloaded Company’s shares for reported $0.25 million on
Stock Earnings The Potential Rise in the Price of Eton Pharmaceuticals Inc (ETON) following insiders activity Eton Pharmaceuticals Inc’s recent filing unveils that its Chief Business Officer Krempa David unloaded Company’s shares for reported $0.25 million
Stock Earnings H.C. Wainwright reiterates Eton Pharmaceuticals Inc (ETON) rating to a Buy In a filing, Eton Pharmaceuticals Inc revealed its Chief Business Officer Krempa David unloaded Company’s shares for reported $0.25 million
Analysts Viewpoint Eton Pharmaceuticals Inc [ETON] 10% Owner makes an insider acquire of 7,930 shares worth 125,484. Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its